Shots:

• The sNDA submission is based on P-II/P-III Clinical trial assessing Dextenza(dexamethasone ophthalmic insert- 0.4mg) vs PBO for the treatment of Ocular Itching associated with allergic conjunctivitis
• Result: At 1EPs for the pooled analysis of P-III clinical trial at Day 8; ocular itching favored DEXTENZA treated participants compared with PBO at all 3-time points: 3 min (1.85 vs 2.55)- 5 min (1.90 vs 2.63)- and 7 min (1.84 vs 2.61)
• Dextenza is a corticosteroid intracanalicular insert placed in the punctum- a natural opening in the inner portion of the lower eyelid- and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives

 ­ Ref: Ocular Therapeutix  | Image: Ocutx